कंपनी का अवलोकन
MetaVia Inc. (MTVA) operates as a clinical-stage biotechnology enterprise dedicated to the development of novel pharmaceutical agents aimed at treating cardiometabolic diseases. The company's primary focus involves the advancement of DA-1241, which functions as a novel G-Protein-Coupled Receptor 119 agonist with development optionality for use as a standalone or combination therapy in Phase 2a clinical trials. This entity functions within the Healthcare sector, specifically the Biotechnology industry, a classification that denotes its reliance on scientific research, clinical development, and regulatory approval processes before commercialization. With a market capitalization of $6.06M and a workforce consisting of 8 employees, MetaVia Inc. represents a micro-cap entity with limited operational scale. These valuation figures, combined with the absence of reported annual revenue, indicate that the company is in an early-stage growth phase where capital is primarily allocated toward research and development rather than revenue generation.
वित्तीय स्वास्थ्य
The company reports a Net Income (TTM) of $-12,973,000 and an EBITDA of $-13,689,000, while annual revenue figures are not available in the current reporting period. The significant negative gap between the reported revenue (which is effectively zero in the context of available data) and the substantial net loss reveals an operational cost structure driven almost entirely by R&D expenditures and clinical trial costs rather than commercial sales. Free Cash Flow stands at $-11,278,500, indicating that the company is consuming cash reserves to fund its developmental pipeline rather than generating liquidity from operations. This negative cash flow suggests a high dependency on external financing or existing cash reserves to sustain ongoing clinical activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the typical financial profile of a pre-revenue biotech firm where no commercial revenue exists to calculate profitability ratios. The company holds $10.31M in cash against $210,000 in debt, resulting in a Debt to Equity ratio of 3.94, which presents a complex picture given the negative equity implied by losses. Despite the high debt-to-equity figure, the current ratio of 1.93 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities, suggesting a manageable immediate liquidity position. However, the Return on Equity of -195.6% and Return on Assets of -62.6% demonstrate that management effectiveness is currently measured by the erosion of shareholder value due to cumulative losses rather than asset appreciation or income generation.
मूल्यांकन आकलन
The Trailing P/E Ratio and Forward P/E Ratio are both listed as N/A, which implies that the company does not generate sufficient positive earnings to support a traditional price-to-earnings valuation metric. In the absence of earnings, investors cannot assess the difference between trailing and forward multiples as a predictor of an earnings trajectory. The Price to Book ratio is 0.52, indicating that the market values the company at significantly less than its accounting book value, a common characteristic for capital-intensive biotechnology firms with intangible assets that are not fully captured on the balance sheet. The Price to Sales ratio and EV/EBITDA are also unavailable or effectively zero due to lack of revenue and negative earnings, preventing the use of these alternative valuation metrics for comparison with profitable peers. The stock has exhibited significant volatility, trading between a 52-Week High of $23.10 and a 52-Week Low of $1.17. Given the low market cap of $6.06M, the current trading price sits well below the 52-week high, reflecting the high-risk nature of clinical-stage assets. The Beta value is 0.34, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting less sensitivity to general market movements despite the inherent risks associated with clinical trial outcomes.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, precluding any analysis of growth rates or comparisons between earnings expansion and revenue expansion. Since the company has not yet achieved commercial sales, there are no dividend yield or payout ratio figures to evaluate, resulting in a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company does not distribute income to shareholders but instead reinvests its limited resources into advancing its clinical pipeline and maintaining regulatory compliance. The overall growth and income profile is characterized by a lack of historical financial performance data, focusing instead on the potential future value of the DA-1241 asset once clinical milestones are met.